News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,502 Results
Type
Article (8039)
Company Profile (141)
Press Release (477225)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166898)
Career Advice (305)
Deals (25748)
Drug Delivery (8)
Drug Development (52925)
Employer Resources (14)
FDA (9771)
Job Trends (8576)
News (238444)
Policy (17935)
Tag
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (488)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33222)
ALS (105)
Alzheimer's disease (980)
Antibody-drug conjugate (ADC) (272)
Approvals (10399)
Artificial intelligence (323)
ASCO (159)
Autoimmune disease (208)
Automation (28)
Bankruptcy (263)
Best Places to Work (6959)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (113)
BioSpace Insights (18)
Biotechnology (89)
Bladder cancer (139)
Brain cancer (29)
Breast cancer (514)
Cancer (3686)
Cardiovascular disease (221)
Career advice (245)
Career pathing (1)
CAR-T (177)
CDMO (7)
Celiac Disease (1)
Cell therapy (482)
Cervical cancer (34)
Clinical research (47959)
Collaboration (1253)
Commercialization (3)
Compensation (1476)
Complete response letters (34)
COVID-19 (758)
CRISPR (64)
C-suite (761)
Cystic fibrosis (85)
Data (5714)
Denatured (4)
Depression (102)
Dermatology (63)
Diabetes (344)
Diagnostics (4198)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (156)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73753)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87758)
Executive appointments (703)
FDA (12433)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (936)
Gene editing (126)
Generative AI (9)
Gene therapy (321)
GLP-1 (291)
Government (947)
Grass and pollen (2)
Guidances (281)
Healthcare (9334)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (59)
Indications (157)
Infectious disease (946)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (258)
Interviews (41)
IPO (12390)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (2)
Kidney cancer (16)
Layoffs (59)
Legal (5196)
Licensing (11)
Liver cancer (44)
Longevity (18)
Lung cancer (512)
Lymphoma (255)
Machine learning (27)
Management (3)
Manufacturing (539)
Marketing (8)
MASH (118)
Medical device (8665)
Medtech (8812)
Mergers & acquisitions (14396)
Metabolic disorders (710)
mRNA (60)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (40)
Neuroscience (1835)
NextGen: Class of 2026 (3150)
Non-profit (850)
Obesity (225)
Opinion (10)
Ovarian cancer (160)
Pain (172)
Pancreatic cancer (201)
Parkinson's disease (201)
Partnered (13)
Patents (480)
Patient recruitment (514)
Peanut (31)
People (41296)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15495)
Phase 2 (21409)
Phase 3 (14438)
Pipeline (7442)
Policy (18)
Postmarket research (1570)
Preclinical (6547)
Press Release (34)
Prostate cancer (191)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (576)
Real estate (3025)
Recruiting (6)
Regulatory (14880)
Reports (21)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (158)
Series B (123)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (89)
Sponsored (5)
Startups (2021)
Stomach cancer (3)
Supply chain (50)
Vaccines (332)
Venture capital (17)
Weight loss (73)
Women's health (82)
Date
Today (70)
Last 7 days (266)
Last 30 days (1511)
Last 365 days (18961)
2026 (12627)
2025 (19272)
2024 (23018)
2023 (26566)
2022 (34610)
2021 (37197)
2020 (33517)
2019 (23275)
2018 (17509)
2017 (18782)
2016 (17947)
2015 (24300)
2014 (21694)
2013 (18153)
2012 (20239)
2011 (20456)
2010 (20361)
Location
Africa (229)
Alabama (74)
Alaska (2)
Arizona (307)
Arkansas (11)
Asia (17939)
Australia (2105)
California (12068)
Canada (3173)
China (530)
Colorado (490)
Connecticut (413)
Delaware (208)
Europe (24893)
Florida (1805)
Georgia (386)
Hawaii (3)
Idaho (46)
Illinois (707)
India (51)
Indiana (317)
Iowa (15)
Japan (411)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1210)
Massachusetts (7900)
Michigan (308)
Minnesota (565)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (118)
New Hampshire (60)
New Jersey (2636)
New Mexico (12)
New York (2831)
North Carolina (1291)
North Dakota (4)
Northern California (6055)
Ohio (280)
Oklahoma (14)
Oregon (18)
Pennsylvania (2267)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5011)
Tennessee (121)
Texas (1958)
United States (39153)
Utah (363)
Vermont (1)
Virginia (155)
Washington D.C. (38)
Washington State (933)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,502 Results for "symbiotix biotherapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MultiValent Biotherapies Launches with $27 Million Series A Financing to Advance Development of Targeted Prostate Cancer Drug Conjugate
June 16, 2026
·
3 min read
Press Releases
AABB Releases New Exam Prep Bundles For its Certified Advanced Biotherapies Professional (CABP) Credentialing Program
March 26, 2026
·
1 min read
Press Releases
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer
December 1, 2025
·
1 min read
Press Releases
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases
October 15, 2025
·
6 min read
Biotherapies Pavilion Back by Popular Demand at 2024 AABB Annual Meeting in Houston, Texas
The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the return of the Biotherapies Pavilion at the 2024 AABB Annual Meeting, which will take place Oct. 19-22 in Houston, Texas.
June 25, 2024
·
2 min read
AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program
The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP)
May 9, 2024
·
2 min read
BioMidwest
NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development
NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.
April 16, 2024
·
4 min read
Genetown
Cambridge Biotherapies Expands Innovative Services with Ketamine Infusions for Opioid-Free Pain Management
Cambridge Biotherapies proudly announces the launch of Ketamine Infusions for Pain and Headache Management, now available at all locations.
May 22, 2024
·
3 min read
Business
NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase.
January 30, 2024
·
4 min read
EVerZom: Therapeutic Ambition in Exosome Biotherapies
EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.
December 13, 2023
·
4 min read
1 of 48,551
Next
